Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg $30
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg $99
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  2. Liu J, et al. 2019. Immunity. 50:600. PubMed
  3. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  4. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  5. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  6. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  7. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  8. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  9. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  10. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  11. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  12. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  13. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  14. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  15. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  16. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  17. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  18. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  19. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  20. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  21. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  22. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  23. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  24. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  25. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  26. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  27. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  28. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  29. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  30. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  31. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  32. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  33. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  34. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  35. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  36. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  37. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  38. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  39. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  40. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  41. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  42. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  43. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  44. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  45. Morales D, et al. 2015. J Virol. 89:337. PubMed
  46. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  47. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  48. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  49. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  50. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  51. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  52. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  53. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  54. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  55. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  56. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  57. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  58. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  59. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  60. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  61. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  62. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  63. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  64. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  65. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  66. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  67. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  68. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  69. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  70. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  71. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  72. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  73. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  74. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  75. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  76. Wu J, et al. 2020. Immunity. 53:115. PubMed
  77. Köchl R, et al. 2020. Elife. 9:00. PubMed
  78. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  79. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  80. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  81. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  82. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  83. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  84. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  85. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  86. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  87. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  88. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  89. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  90. Wan X, et al. 2018. Nature. 560:107. PubMed
  91. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  92. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  93. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  94. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  95. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  96. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  97. Yang J, et al. 2020. Nature. 586:572. PubMed
  98. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  99. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  100. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  101. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  102. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  103. Du J, et al. 2018. AMB Express. 8:158. PubMed
  104. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  105. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  106. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  107. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  108. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  109. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  110. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  111. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  112. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  113. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  114. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  115. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  116. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  117. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  118. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  119. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  120. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  121. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  122. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  123. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  124. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  125. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  126. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  127. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  128. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  129. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  130. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  131. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  132. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  133. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  134. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  135. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  136. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  137. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  138. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  139. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  140. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  141. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  142. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  143. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  144. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  145. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  146. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  147. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  148. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  149. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  150. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  151. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  152. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  153. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  154. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  155. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  156. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  157. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  158. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  159. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  160. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  161. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  162. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  163. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  164. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  165. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  166. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  167. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  168. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  169. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  170. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  171. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  172. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  173. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  174. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  175. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  176. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  177. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  178. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  179. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  180. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  181. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  182. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  183. Li H, et al. 2022. iScience. 25:104481. PubMed
  184. Wang X, et al. 2022. Elife. 11:. PubMed
  185. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  186. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  187. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  188. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  189. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  190. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  191. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  192. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  193. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  194. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  195. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  196. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  197. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  198. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  199. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  200. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  201. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  202. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  203. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  204. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  205. Xie L, et al. 2020. Infect Immun. :88. PubMed
  206. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  207. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account